Results 41 to 50 of about 25,109 (253)

AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Molecular Cancer Therapeutics, 2023
HER3 is a unique member of the EGFR family of tyrosine kinases, which is broadly expressed in several cancers, including breast, lung, pancreatic, colorectal, gastric, prostate, and bladder cancers and is often associated with poor patient outcomes and ...
Weining Weng, Tao Meng, Junyi Pu, Linjie Ma, Yi Shen, Zhaohui Wang, Rong Pan, Mingqiao Wang, Caiwei Chen, Lijun Wang, Jianjian Zhang, Biao Zhou, Siyuan Shao, Y. Qian, Shu-Hui Liu, Wenhao Hu, Xun Meng   +16 more
semanticscholar   +1 more source

NOTCH1 signaling promotes protein stability of HER3 through the AKT pathway in squamous cell carcinoma of head and neck

Oncogenesis, 2021
Epidermal growth factor receptor (EGFR) remains the sole druggable molecular target other than the PD1/PD-L1 pathway with meaningful clinical benefit in squamous cell carcinoma of head and neck (SCCHN).
Yi-Ping Wang, I-Ju Liu, Kai-Chi Chen, Han-Chung Wu   +3 more
doaj   +1 more source

Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer

Oncotarget, 2016
HER3/ErbB3 has emerged as a new therapeutic target for cancer. Currently, more than a dozen anti-HER3 antibodies are in clinical trials for treatment of various cancers. However, limited understanding of the complex HER3 signaling in cancer and lack of established biomarkers have made it challenging to stratify cancer patients who can benefit from HER3
Zhang, Shu, Mukherjee, Seema, Fan, Xuejun, Salameh, Ahmad, Mujoo, Kalpana, Huang, Zhao, Li, Leike, Salazar, Georgina To'a, Zhang, Ningyan, An, Zhiqiang   +9 more
openaire   +3 more sources

Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients

BMC Cancer, 2017
Background The HER2-HER3 heterodimer significantly decreases survival in breast cancer patients. However, the prognostic value of HER2-HER3 overexpression remains unknown in gastric cancer (GC).
Guo-dong Cao, Ke Chen, Bo Chen, Mao-ming Xiong   +3 more
doaj   +1 more source

Systemic HER3 ligand-mimicking nanobioparticles enter the brain and reduce intracranial tumour growth

Nature Nanotechnology
Crossing the blood–brain barrier (BBB) and reaching intracranial tumours is a clinical challenge for current targeted interventions including antibody-based therapies, contributing to poor patient outcomes.
Felix Alonso-Valenteen, Simoun Mikhael, Hongqiang Wang, Jessica D. Sims, M. Taguiam, J. Teh, Sam Sances, Michelle Wong, Tianxin Miao, Dustin Srinivas, Nelyda Gonzalez-Almeyda, Ryan H Cho, Romny Sanchez, Kimngan Nguyenle, Erik Serrano, Briana N Ondatje, R. Benhaghnazar, H. B. Gray, Z. Gross, John Yu, Clive N. Svendsen, R. Abrol, L. Medina-Kauwe   +22 more
semanticscholar   +1 more source

HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma

OncoTarget, 2023
Colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) are highly metastatic cancers with poor survival rates. The tumor microenvironment has been shown to play a critical role in cancer progression and response to therapies.
Omkar Desai, Rui Wang
semanticscholar   +1 more source

Identification of Potent Inhibitors Targeting EGFR and HER3 for Effective Treatment of Chemoresistance in Non-Small Cell Lung Cancer

Molecules, 2023
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer. Despite the existence of various therapeutic options, NSCLC is still a major health concern due to its aggressive nature and high mutation rate.
J. Jampílek, Chan Kyung Kim, A. Dera, S. Zaib, Nadia Hussain, Neha Rana, Hira Javed, Imtiaz Khan   +7 more
semanticscholar   +1 more source

Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model

International Journal of Molecular Sciences, 2023
Pancreatic cancer (PC) is one of the most aggressive malignancies. A combination of targeted therapies could increase the therapeutic efficacy in tumors with heterogeneous target expression.
Tianqi Xu, A. Schulga, E. Konovalova, Sara S Rinne, Hongchao Zhang, O. Vorontsova, A. Orlova, S. Deyev, V. Tolmachev, A. Vorobyeva   +9 more
semanticscholar   +1 more source

High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck. [PDF]

PLoS ONE, 2013
PURPOSE:Tumors with oncogenic dependencies on the HER family of receptor tyrosine kinases (RTKs) often respond well to targeted inhibition. Our previous work suggested that many cell lines derived from squamous cell carcinomas of the head and neck ...
David S Shames, Juliet Carbon, Kim Walter, Adrian M Jubb, Cleopatra Kozlowski, Tom Januario, An Do, Ling Fu, Yuanyuan Xiao, Rajiv Raja, Brittany Jiang, Ashi Malekafzali, Howard Stern, Jeff Settleman, Timothy R Wilson, Garret M Hampton, Robert L Yauch, Andrea Pirzkall, Lukas C Amler   +18 more
doaj   +1 more source

Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux

Experimental Hematology & Oncology
Ovarian cancer (OC) is the most pathogenic gynecological malignant tumor in the world. Due to the difficulty of early diagnosis, most of patients developed chemo-resistance and recurrence during/after chemotherapy.
Ye Zhang, Jian-Ge Qiu, Wei Wang, Fan-Li Sun, Xue Wang, Wenjie Liu, Xiao-Yu Jia, Hongbin Ji, Lin Wang, Bing-Hua Jiang   +9 more
semanticscholar   +1 more source